https://doi.org/10.55788/c9bc0a22
“Anatomically complex coronary artery disease (CAD) still presents challenges, despite the advancements that have been made with PCI plus DES,” said Prof. Byeong-Keuk Kim (Yonsei University Hospital, South Korea) [1]. The OCCUPI trial (NCT03625908) aimed to assess the possible clinical benefits of OCT for patients with complex lesions. This multicentre, open-label, randomised trial included 1,604 participants with complex coronary lesions, who were allocated to the OCT-guided PCI arm or the angiography-guided PCI arm [1,2]. The primary endpoint was MACE at 1 year of follow-up.
The primary endpoint favoured the OCT-guided arm, with a lower event rate in this arm than in the control arm (4.6% vs 7.4%; HR 0.62; 95% CI 0.41–0.93; P=0.023) [1]. Looking at the individual components of this endpoint, Prof. Kim and co-investigators found that the occurrence of spontaneous myocardial infarction (MI; 0.9% vs 2.4%), target-vessel related MI (0.6% vs 2.1%), and target vessel revascularisation (1.5% vs 4.1%) were all significantly in favour of the OCT-guided arm. “Patients meeting all the criteria of stent optimisation in the OCT-guided arm were less likely to experience MACE than patients who did not meet all 3 criteria,” added Prof. Kim (2.9% vs 8.6%; HR 0.33; 95% CI 0.17–0.65; P=0.001).
“The findings of the OCCUPI trial support the therapeutic benefit of OCT as an effective intravascular imaging modality in treating complex lesions,” concluded Prof. Kim.
- Kim B-K, et al. Optical coherence tomography-guided coronary intervention in patients with complex lesions: the OCCUPI randomised clinical trial. HOTLINE 11, ESC Congress 2024, 30 Aug–02 Sept, London, UK.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Low-dose 3-drug pill GMRx2 shows promise in lowering BP Next Article
REC-CAGEFREE I: Can we avoid permanent stenting with drug-coated balloons? »
« Low-dose 3-drug pill GMRx2 shows promise in lowering BP Next Article
REC-CAGEFREE I: Can we avoid permanent stenting with drug-coated balloons? »
Table of Contents: ESC 2024
Featured articles
Meet the Expert: Dr Abdullahi Mohamed on Iron Deficiency in Patients with HF
2024 ESC Guidelines in a Nutshell
Guidelines for the management of elevated blood pressure and hypertension
Guidelines for the management of chronic coronary syndromes
Guidelines for the management of atrial fibrillation
Guidelines for the management of peripheral artery and aortic diseases
Crossing Borders in Arrhythmia
EPIC-CAD: What is the best antithrombotic approach in high-risk AF plus stable CAD?
OCEANIC-AF: Asundexian inferior to apixaban for ischaemic stroke prevention in AF
MIRACLE-AF: Elegant solution to improve AF care in rural China
SUPPRESS-AF: What is the value of adding LVA ablation to PVI in AF?
Clever Ideas for Coronary Artery Disease
ABYSS: Can beta-blocker safely be interrupted post-MI?
SWEDEGRAFT: Can a no-touch vein harvesting technique improve outcomes in CABG?
Bioadaptor meets expectations in reducing target lesion failures in coronary artery disease
REC-CAGEFREE I: Can we avoid permanent stenting with drug-coated balloons?
OCCUPI: OCT-guided PCI improves outcomes in complex CAD
Highway to Hypertension Control
Low-dose 3-drug pill GMRx2 shows promise in lowering BP
Is administering BP medication in the evening better than in the morning?
VERONICA: Improving BP control in Africa with a simple strategy
High-end Trials in Heart Failure
FINEARTS-HF: Finerenone improves outcomes in heart failure with preserved ejection fraction
MRAs show varied efficacy in heart failure across ejection fractions
MATTERHORN: Transcatheter repair matches surgery for HF with secondary mitral regurgitation
RESHAPE-HF2: Not a “tie-breaker” for TEER in heart failure
Practical Gains in Screening and Diagnostics
STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines
SCOFF: To fast or not to fast, that’s the question
WESTCOR-POC: Point-of-care hs-troponin testing increases emergency department efficiency
PROTEUS: Can AI improve decision-making around stress echocardiography?
RAPIDxAI: Can AI-augmented chest pain assessment improve cardiovascular outcomes?
Miscellaneous Achievements in Cardiology
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy
Does RAS inhibitor discontinuation affect outcomes after non-cardiac surgery?
Novel approach to managing severe tricuspid regurgitation proves its value
NOTION-3: TAVI plus PCI improves outcomes in CAD plus severe aortic stenosis
RHEIA: TAVI outperformed surgery in women with aortic stenosis
Related Articles
November 7, 2024
HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com